Noxopharm is an Australian publicly-listed (ASX: NOX) clinical stage drug development company that has a primary focus on the development of Veyonda and is the major shareholder in Nyrada Inc, a spin-off company developing a pipeline of non-oncology drugs.
Noxopharm Limited belongs to Health Care sector and under industry of Biotechnology. You can get more information about this company via their website: http://www.noxopharm.com.
This a small cap company with market cap of 192 millions.
Compared to Market and Sector
The following table compares the company to Market and Sector based on Earning, Price/Earning ratio(P/E), Price/Book ratio (P/B) and PE growth.
Company PE is less than both sector and market. while Company PB is greater than both sector and market. On the other hand, Company Earning is less than both sector and market.
Dividend Growth Chart
The following chart shows you how nox dividend grows in the recent years.